Smith & Nephew SNATS, Inc. $SNN Holdings Reduced by Eagle Global Advisors LLC

Eagle Global Advisors LLC decreased its position in Smith & Nephew SNATS, Inc. (NYSE:SNN) by 8.3% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 55,400 shares of the medical equipment provider’s stock after selling 5,000 shares during the period. Eagle Global Advisors LLC’s holdings in Smith & Nephew SNATS were worth $1,697,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Ballentine Partners LLC bought a new position in Smith & Nephew SNATS in the 2nd quarter worth about $263,000. Oliver Luxxe Assets LLC bought a new position in Smith & Nephew SNATS in the 2nd quarter worth about $5,176,000. Scharf Investments LLC grew its position in Smith & Nephew SNATS by 0.3% in the 2nd quarter. Scharf Investments LLC now owns 2,083,513 shares of the medical equipment provider’s stock worth $63,818,000 after purchasing an additional 6,993 shares during the last quarter. Park Avenue Securities LLC grew its position in Smith & Nephew SNATS by 6.3% in the 2nd quarter. Park Avenue Securities LLC now owns 9,789 shares of the medical equipment provider’s stock worth $300,000 after purchasing an additional 583 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Smith & Nephew SNATS by 4.4% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 36,077 shares of the medical equipment provider’s stock valued at $1,092,000 after acquiring an additional 1,512 shares in the last quarter. Institutional investors own 25.64% of the company’s stock.

Analysts Set New Price Targets

SNN has been the subject of several recent analyst reports. Canaccord Genuity Group increased their price objective on shares of Smith & Nephew SNATS from $28.00 to $36.00 and gave the company a “hold” rating in a report on Monday, August 18th. Wall Street Zen upgraded shares of Smith & Nephew SNATS from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 30th. Six research analysts have rated the stock with a Hold rating, According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $36.00.

Smith & Nephew SNATS Trading Up 0.5%

Shares of NYSE:SNN opened at $35.44 on Friday. The stock has a market capitalization of $15.43 billion, a price-to-earnings ratio of 16.41, a PEG ratio of 0.97 and a beta of 0.71. Smith & Nephew SNATS, Inc. has a 1-year low of $23.69 and a 1-year high of $38.79. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.40 and a current ratio of 3.00. The company has a 50 day moving average price of $35.65 and a 200 day moving average price of $30.93.

Smith & Nephew SNATS Cuts Dividend

The firm also recently announced a semi-annual dividend, which will be paid on Friday, November 7th. Investors of record on Friday, October 3rd will be issued a dividend of $0.285 per share. This represents a yield of 210.0%. The ex-dividend date is Friday, October 3rd. Smith & Nephew SNATS’s dividend payout ratio (DPR) is presently 41.20%.

Smith & Nephew SNATS Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.